Psychedelics in Psychiatry: A Wakeup Call for Clinicians in the Age of Policy Reform

To the Editor: On April 18, 2026, President Donald Trump signed an executive order directing the US Food and Drug Administration (FDA) to fast-track review of psychedelic drugs, including psilocybin and ibogaine, and allocating $50 million in federal funding toward their clinical development.¹ This unprecedented policy action places psychedelics firmly within mainstream health care discourse and signals a paradigm shift with profound implications for global psychiatry. We write to argue that clinicians—not politicians, podcasters, or policy advocates—must now lead this renaissance with scientific rigor and ethical clarity.

The therapeutic case for psychedelics is no longer fringe. Psilocybin-assisted therapy has demonstrated efficacy in major depressive disorder in randomized clinical trials, with large effect sizes maintained at 4-week follow-up.² A head-to-head comparison with escitalopram in major depressive disorder found no significant difference on the primary outcome, with secondary outcomes generally favoring psilocybin.³ 3,4-Methylenedioxymethamphetamine–assisted therapy demonstrated a significant reduction in posttraumatic stress disorder (PTSD) symptom severity over placebo in a phase 3 randomized controlled trial.⁴ Ketamine has shown rapid antidepressant efficacy in treatment-resistant major depression in a 2-site randomized controlled trial.⁵ Microdosing with low-dose lysergic acid diethylamide is physically safe and produces measurable acute neurological and behavioral effects in healthy adults, though repeated dosing has not yet shown sustained cognitive or mood benefits, underscoring the need for further research.⁶

The executive order’s specific focus on ibogaine, a compound with documented benefit for PTSD and opioid use disorder in veteran populations, highlights both the promise and the peril of political acceleration. Ibogaine is associated with serious cardiac arrhythmias through QT prolongation and has been linked to sudden death in treatment settings⁷; the FDA had historically resisted its study for precisely this reason. Speed-running regulatory review in response to advocacy, however well intentioned, risks repeating historical mistakes. At the domestic level, any rescheduling of ibogaine from Schedule I would lower the administrative and legal barriers for US psychiatric researchers, potentially accelerating the very evidence base the field currently lacks. This is a genuine and welcome benefit, but it does not substitute for the structured, safety-conscious regulatory process that ibogaine’s cardiac risk profile demands. Psychiatry’s first wave of psychedelic enthusiasm collapsed partly because enthusiasm outpaced evidence. We cannot afford a second collapse.

For clinicians in low-and middle-income countries, including India, the implications are equally significant. India’s Narcotic Drugs and Psychotropic Substances (NDPS) Act of 1985 continues to restrict psychotropic research outside narrow medicinal channels.⁸ With the United States (historically the global enforcer of Schedule I classifications) now actively promoting psychedelic therapeutics, the political calculus for regulatory reform has shifted. India carries one of the world’s largest burdens of treatment-resistant depression and PTSD yet lacks structured pathways for psychedelic research. The 2014 NDPS amendment introduced “essential narcotic drugs” for medical use, a foundation that the Indian Psychiatric Society and Central Drugs Standard Control Organisation should now actively build upon.

Several clinical priorities are nonnegotiable as this field expands. Rigorous pretreatment screening for psychosis-spectrum vulnerability and bipolar disorder is essential, as psychedelics carry genuine risks of precipitating or exacerbating these conditions.⁹ Structured therapeutic settings with trained clinicians are not optional adjuncts; they are integral to outcomes. The public discourse must also clearly distinguish between controlled therapeutic use, investigational microdosing protocols, and recreational misuse. Conflating these categories disserves patients and erodes institutional trust.

The Trump executive order has opened doors that cautious regulation had kept shut. However, open doors require careful navigation. The primary care and psychiatric communities have a collective responsibility to ensure that the psychedelic renaissance—real, scientifically grounded, and now politically unstoppable—is built on evidence, ethics, and patient safety rather than on the enthusiasm of an Oval Office signing ceremony.¹⁰ The mushrooms, the Molly, and the acid have been waiting. Let us make sure they are finally put to work the right way.

Article Information

Published Online: October 20, 2026. https://doi.org/10.4088/PCC.26lr04256
© 2026 Physicians Postgraduate Press, Inc.
Prim Care Companion CNS Disord 2026;28(5):26lr04256
To Cite: Garg S, Pattojoshi A. Psychedelics in psychiatry: a wakeup call for clinicians in the age of policy reform.
Prim Care Companion CNS Disord. 2026;28(5):26lr04256.
Author Affiliations: Department of Psychiatry, Shri Guru Ram Rai Institute of Medical and Health Sciences, Patel Nagar, Dehradun, Uttarakhand, India (Garg); Department of Psychiatry, Hi-Tech Medical College, Bhubaneswar, Odisha, India (Pattojoshi).
Corresponding Author: Shobit Garg, MD, DPM, Department of Psychiatry, Shri Guru Ram Rai Institute of Medical and Health Sciences, Shri Guru Ram Rai University, Dehradun, Uttarakhand – 248001, India ([email protected]).
Financial Disclosure: None.
Funding/Support: None.
Additional Information: AI-assisted tools were used for language refinement. All intellectual content was reviewed and approved by the authors.
ORCID: Shobit Garg: https://orcid.org/0000-0001-5913-9021